Showing results (11-20 of 27) with videos related to
Sort By:
Pageof 3
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 26, 2005
Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-hodgkin lymphomaRobert M Dean, Daniel H Fowler, Wyndham H Wilson, et al.American Journal of Hematology|January 22, 2019
Progression with clinical features is associated with worse subsequent survival in multiple myelomaRajshekhar Chakraborty, Hien D Liu, Lisa Rybicki, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 17, 2013
Host lymphocyte depletion as a strategy to facilitate early full donor chimerism after reduced-intensity allogeneic stem cell transplantationRachel B Salit, Daniel H Fowler, Robert M Dean, et al.British Journal of Haematology|October 14, 2009
Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposideRobert M Dean, Brad Pohlman, John W Sweetenham, et al.Leukemia & Lymphoma|December 30, 2020
Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysisAgrima Mian, Wei Wei, Allison M Winter, et al.Leukemia & Lymphoma|August 13, 2009
High rate of survival in transformed lymphoma after autologous stem cell transplant: pathologic analysis and comparison with de novo diffuse large B-cell lymphomaStephen D Smith, Brian J Bolwell, Anjali S Advani, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2012
Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignanciesRachel B Salit, Daniel H Fowler, Wyndham H Wilson, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 15, 2019
Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell TransplantationBrian T Hill, Lisa A Rybicki, Theresa A Urban, et al.Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|June 8, 2022
Toxicity analysis of busulfan pharmacokinetic therapeutic dose monitoringKelly J Gaffney, Theresa A Urban, Mariana Lucena, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 3, 2005
Establishing a platform for immunotherapy: clinical outcome and study of immune reconstitution after high-dose chemotherapy with progenitor cell support in breast cancer patientsClaude Sportès, Nicole J McCarthy, Frances Hakim, et al.Pageof 3